Central nervous system (CNS) complications have been described in patients undergoing allogeneic hematopoietic cell transplantation (alloHCT). Cerebrospinal fluid (CSF) analysis is included in the diagnostic workup in patients with neurological symptoms after alloHCT. CSF donor-recipient chimerism analysis usually is not used to evaluate patients with neurological complications after alloHCT. To assess the potential contribution of CSF donor-recipient chimerism in patients with neurological complications, we analyzed 85 CSF samples from 50 patients with neurological complications after alloHCT. After alloHCT, 21 patients showed the presence of recipient-derived DNA. In 13 of these patients, recurrence of the underlying disease was detected in CSF. There was a moderate correlation between the recipient DNA percentage as detected by short tandem repeat (STR) amplification and the cell concentration in CSF (Spearmann r: 0.66 P = 0.004). The percentage of cells with immunophenotypic abnormalities from patients relapsing in the CNS detected by flow cytometry showed a strong correlation with the percentage of recipient-derived DNA in CSF assessed by STR analysis (Spearmann r: 0.83 P = 0.0008). Donor-recipient chimerism analysis in CSF in patients with neurological symptoms after alloHCT is a practical, feasible and useful complementary method to the already established methodologies included in the diagnostic workup.
INTRODUCTION
Neurological complications after allogeneic hematopoietic cell transplantation (alloHCT) have been reported with a varying incidence between 8% and 42% in bone marrow recipients. 1 Among this type of complication, the incidence of central nervous system (CNS) relapse of the underlying disease ranged from 2.9% to 11% in patients undergoing alloHCT. 2 To begin a proper treatment as early as possible, an accurate and prompt diagnosis is mandatory. However, because of the several etiologies of neurological symptoms and the lack of optimal diagnostic methods, diagnosis could be challenging. In addition to neurological evaluation, several methods can be used to establish an accurate diagnosis.
Cerebrospinal fluid (CSF) examination constitutes a part of the diagnostic work-up of patients with neurological symptoms after alloHCT. Cytological analysis is considered to be the gold standard for the detection of malignant cells in CSF. 3 However, cytology exhibits limitations regarding sensitivity and positive predictive value in the identification of malignant cells. Characterization of CSF cells using flow cytometry (FC) improved the detection of malignant and non-malignant cells and constitutes a useful diagnostic complement. 4 The reported use of molecular biology techniques in CSF cells in patients undergoing alloHCT is scarce, and these reports mostly refer to the pediatric population involving small patient cohorts. 5, 6 Donor-recipient chimerism routinely used to evaluate hematopoietic chimerism following alloHCT usually does not constitute a part of the CSF analysis in patients with neurological symptoms. Few reports describe the clinical utility of CSF chimerism analysis in patients after alloHCT. 7, 8 Furthermore, whereas several reports compare cytology with FC in the identification of CSF cells, there is no comparison between FC and chimerism analysis in this type of sample. 4, 9, 10 In this study, we evaluated the potential contribution of CSF donor-recipient chimerism analysis in patients with neurological symptoms following alloHCT.
PATIENTS AND METHODS

Patient characteristics
Patients presenting with neurological symptoms after alloHCT who required a lumbar puncture for diagnostic purposes were included in the study. Patients who received prophylactic treatment to prevent CNS disease were excluded from the study.
A total of 50 patients with neurological symptoms after alloHCT were investigated for the chimeric status in CSF. In nine patients, lumbar puncture was performed in the course of their second transplant. Precautions were taken to avoid peripheral blood contamination during lumbar puncture. Presenting neurological symptoms included peripheral deficits such as weakness or numbness, alteration of consciousness, seizures, vomiting, recurrent headaches, nausea and changes in vision among others.
Transplantation procedure and GvHD prophylaxis was performed as previously described. 11 After transplantation, all the included patients achieved complete hematological remission.
This study was approved by the Ethics Committee of the Albert Ludwigs University, Freiburg, Germany. Written informed consent was obtained from the patients in accordance with the declaration of Helsinki.
examination. CSF samples contaminated with blood as detected by visual inspection or samples with 410 red blood cells/μL were not included in the analysis. Cell counts were performed with a hemocytometer (Paul Marienfeld, Lauda-Königshofen, Germany) using a × 40 high-power microscope (Olympus, Hamburg, Germany).
DNA isolation and chimerism analysis CSF specimens were centrifuged and genomic DNA was isolated from the cell pellet and also from peripheral blood using commercial kits (QIamp Blood Mini Kit; Qiagen GmbH, Hilden, Germany). Chimerism detection in blood and CSF was assessed with polymorphic short tandem repeats (STRs) amplified by PCR. Prior to STR testing, whole-genome amplification (WGA) was performed in all CSF samples using the REPLI-g Mini Kit (Qiagen GmbH) according to the manufacturer's recommendations. Briefly, 2.5 μL of DNA template was added to sample buffer and the master mix containing the DNA polymerase. The sample was incubated overnight at 30°C and the polymerase was heat inactivated for 3 min at 65°C. Chimerism testing in CSF was performed in parallel in the DNA obtained either with or without WGA. A panel of five microsatellites was included in the study for chimerism testing (D1S80, SE33, THO1, D12S391, D4S2366). Hematopoietic chimerism was performed in the peripheral blood simultaneously with CSF using the same STR markers in both types of samples as previously described. 12 The resulting PCR product was analyzed using the Fragment Analyzer capillary electrophoresis system (Advanced Analytical Technologies GmbH, Heidelberg, Germany), and the chromatograms were analyzed with the ProSize software (Advanced Analytical Technologies GmbH, Heidelberg, Germany). Quantification of mixed chimerism (MC) was performed using a previously described algorithm. 13 FC and microbiological analysis CSF samples were analyzed by FC with monoclonal antibodies, which were selected based on prior hematological diagnoses. Specific markers for lineage confirmation were used in hematological malignancies, such as AML, ALL, CLL and non-Hodgkin lymphoma. Samples were run onto a FACSCanto II flow cytometer (Becton Dickinson, Mountain View, CA, USA).
FC data were analyzed using the DIVA software (Becton Dickinson, Mountain View, CA, USA). In cases with a low cell count, the samples were analyzed by incubating the cells in multiwell adhesion slides with the appropriate monoclonal antibodies (Paul Marienfeld, Lauda-Königshofen, Germany), and the cells were counted under a high-power field microscope. Anti-CD3 monoclonal antibodies were routinely used to stain T-lymphocytes. FC findings were classified into three categories: positive, negative, and uncertain. A positive sample was defined as those in which immunophenotipically abnormal cells were found. Negative samples did not show an abnormal immunophenotype. Specimens included in the uncertain category did not contain sufficient immunephenotypic abnormalities for a positive diagnosis.
All CSF and blood samples were screened for several types of viruses: adenovirus, BK virus, JC virus, CMV, EBV, HSV, VZV, and human herpesvirus-6, by PCR.
Statistical analysis
Common statistical parameters were calculated using the GraphPad version 4.0 software (La Jolla, CA, USA). Correlation coefficients were calculated by the Spearman rank correlation coefficient analysis. For the comparison of qualitative or quantitative variables without a normal distribution, Mann-Whitney, Wilcoxon signed-rank test or Kruskal-Wallis tests were used. Quantitative variables were analyzed with Student's paired t-test or Fisher's exact test in the case of small numbers. All tests were two sided, accepting P ⩽ 0.05 as indicating a statistically significant difference.
RESULTS
Clinical characteristics of the 50 patients with and without MC in CFS after alloHCT are depicted in Table 1 . A total of 85 CSF samples obtained from 50 patients were included in the study. From the 85 samples, 12 CSF specimens representing 14% of all samples were successfully amplified for STR analysis only after WGA, whereas for the rest of the CSF samples STR PCR performance was similar either for the DNA isolated directly from the cells in CSF or after WGA. No allele dropout was detected in the STR analysis. Repeat CSF sampling was performed in 19 patients. The median number of CSF samples per patient in this group was 3 (range 2-5). Most such samples came from patients relapsing in the CNS after transplantation. Repeated lumbar puncture did not increase MC detection rate in CSF.
After alloHCT, in 21 patients the presence of DNA of recipient origin in CSF was detected by STR amplification. Three patients with a mixture of donor and recipient genotype in CSF showed simultaneously mixed hematopoietic chimerism. These three patients had a concomitant relapse in the peripheral blood and in the CNS (two with ALL and one with CLL). In the remaining 47 patients with or without MC in CSF, complete donor chimerism (CC) was detected in the peripheral blood at the same time point as CSF sampling. These patients with CC were in complete hematological remission at the time of CSF sampling.
Of the 21 patients with MC in CSF, in 13 of them recurrence of the underlying disease in the CNS was detected. In two patients, viral meningitis was diagnosed. One patient showed clinical features compatible with Guillan-Barre syndrome. In the remaining five patients with MC in CSF, the etiology of the neurological symptoms could not be established based on the CSF findings.
Patients relapsing in the CNS in whom MC was found were distributed according to the initial diagnosis as follows: AML Abbreviations: CC = complete donor chimerism; CNS = central nervous system; CSF = cerebrospinal fluid; MC = mixed chimerism; NHL = nonHodgkin lymphoma; Tx = transplantation. a PCR was positive for VZV in one case and for JC virus in the remaining patient.
b PCR was positive for human herpesvirus-6 in three cases and for EBV in the remaining two cases. Table 2 . There was a moderate correlation between the recipient DNA percentage as detected by STR amplification and the cell concentration in CSF (Spearmann r: 0.66 P = 0.004). The percentage of cells with immunophenotypic abnormalities from patients relapsing in the CNS detected by FC showed a strong correlation with the percentage of recipient-derived DNA in CSF assessed by STR analysis (Spearmann r: 0.83 P = 0.0008 and Bland Altman analysis) with a slope close to 1, indicating the absence of systemic bias ( Figure 1 and Supplementary Figure S1) .
To analyze the general STR analysis performance, the truepositive rate (sensitivity) and false-positive rate (1 − specificity) was plotted in a receiver-operating characteristic space. The receiveroperating characteristic curve showed an area under the curve of 0.95 (95% confidence interval, 0.87-1.03) that resulted a statistical significance (P o 0.05) for STR analysis when tested in patients relapsing in the CNS (Supplementary Figure S2) .
In the remaining eight patients with MC in CSF, the mean percentage of recipient DNA and the mean cellular concentration in CSF were significantly lower in comparison with the group of patients with relapse in the CNS. A representative example of a STR analysis from a patient with MC in CSF is shown in Figure 2 .
In 29 patients, CC was detected after transplantation in CSF. Repeated lumbar puncture resulted in CC in five patients. FC analysis of CSF cells in patients with CC resulted in CD3-positive cells in 28 patients. In addition, two patients showed a low percentage of CD19-positive cells.
One patient initially diagnosed with AML and with CC in CSF relapsed in the CNS. FC analysis in this particular patient revealed 1% of leukemic blasts. In five patients with CC in CSF, viral meningitis was detected. The mean cellular concentration in patients with CC in CSF was 14 cells/μL (range: 2-85 cells/μL) and was significantly lower in comparison with the group of patients relapsing in the CNS (P o 0.05).
DISCUSSION
In this study, we examined the potential contribution of chimerism analysis on CSF in patients with neurological symptoms after allogeneic HCT. Almost half of the patients (42%) included in the present study showed the presence of cells of recipient origin in CSF. In the majority of these patients with MC in CSF, recurrence of the underlying disease was detected.
FC has been routinely used for the detection and characterization of CSF cells as part of the diagnostic work-up in patients with lymphoid and myeloid malignancies. However, the diagnosis of CSF abnormalities by FC is not devoid of drawbacks such as the presence of normal or reactive lymphocytes, low cell count and shifting of aberrant antigen expression at relapse.
14 In addition, lymphoma or leukemia can shed only few abnormal cells into the CSF. 15 Several reports have compared cytology with FC showing a broad range of concordant results. 4, 9, 10 Our FC findings and chimerism analysis in the group of patients relapsing in the CNS showed a high concordance degree. With the exception of three patients, agreement was observed between FC and chimerism analysis in 11 patients. Furthermore, the percentage of abnormal cells in CSF detected by FC was highly correlated with the percentage of recipient-derived DNA assessed by STR analysis. Two patients relapsing in CNS with MC in CSF and uncertain FC findings showed the loss of an aberrant marker found in the initial diagnosis sample. Shift of aberrant antigen expression at relapse has been reported in up to 73% of the patients with acute leukemia.
14 As previously suggested, a possible reason is that immunophenotypically different leukemia subclones are included in the initial sample and these subclones show different chemotherapy sensitivity. The leukemia cell subpopulation with aberrant antigen expression may be sensitive to chemotherapy, whereas leukemia cells without aberrant antigen expression are resistant and therefore may be present at relapse. 16 Unlike FC, clonal evolution of the underlying disease after transplantation may not be a limitation for MC detection in CSF. These last findings highlight the utility of chimerism analysis in CSF cells as a complementary method of the already established methodologies. Nevertheless, one caveat of our study is the lack of cytomorphological examination of CSF cells. It is well established that the combined analysis of cytomorphology and FC enhances the detection rate of abnormal cells in CSF. In addition, cytostatic therapy induces cytogenetic changes, which in turn may result in modifications in the used STR modifying in this way the diagnostic yield of chimerism detection. 17 In one patient with CC in CSF, only 1% of abnormal cells were detected by FC. As previously shown, STR analytical sensitivity for hematopoietic chimerism detection is between 3% and 5%. 18 Although a formal sensitivity comparison between both methodologies was not performed, it can be argued that failure to detect MC in CSF cells in this particular patient is possibly due to sensitivity limitations in STR analysis.
All patients with MC in CSF relapsing or not in the CNS showed variable amounts of CD3-positive cells. Residual cells either of donor or recipient origin within the CSF in transplanted patients have been described. 7 These types of CSF cells are poorly characterized and their significance is unclear. In our study, although precautions were taken during lumbar puncture, we can not completely exclude CSF contamination with nonhematopoietic recipient cells.
In the group of patients with CC in CSF, a low percentage of cells were found. These cells were found to be CD3-positive cells of donor origin. Again, the absence of abnormal cells in CSF in patients with CC suggests that STR analysis in CSF is a useful complementary method and may result particularly informative in patients without relapse in CNS after alloHCT.
In five patients with CC in CSF, viral meningitis was detected. Previous observations indicate that the engrafted donor-derived leukocytes enter into the CNS following alloHCT. 19 Under pathological conditions such as meningitis or induced by the preparatory regimen, the blood-brain barrier becomes permeable, and as a result, the leukocyte migration rate into the brain might be increased.
It is worth noting that successful STR amplification was achieved in 14% of the CSF samples only after WGA. Despite the fact that WGA is an additional step in the whole process, our results suggest that such a step must be included in order to increase the diagnostic yield.
Taking in consideration the benefits and limitations of current diagnostic tests, we conclude that chimerism analysis in CSF in patients presenting neurological symptoms after alloHCT is a practical and useful complementary method to the already established methodologies included in the diagnostics work-up. Figure 2 . A representative example of STR analysis (STR marker: SE33) in peripheral blood and CSF from a patient relapsing in the CNS after alloHCT. Form top to bottom, patient CSF specimen after alloHCT, patient peripheral blood after alloHCT, donor and patient peripheral blood before transplantation. Peripheral blood and CSF sampling were performed simultaneously.
